翻訳と辞書 |
Deferasirox
Deferasirox (marketed as Exjade,〔Official manufacturer website including information for health care professionals about indications, dosing, safety and more: http://www.exjade.com/〕 Desirox, Defrijet, Desifer...) is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta-thalassemia and other chronic anemias.〔 (Free full text )〕 It is the first oral medication approved in the USA for this purpose. It was approved by the United States Food and Drug Administration (FDA) in November 2005.〔〔 According to FDA (May 2007), renal failure and cytopenias have been reported in patients receiving deferasirox oral suspension tablets. It is approved in the European Union by the European Medicines Agency (EMA) for children 6 years and older for chronic iron overload from repeated blood transfusions.〔(Exjade - deferasirox ), from EMA website〕〔(Turning a blind eye to deferasirox's toxicity? ), ''The Lancet'', Volume 381, No. 9873, p1183–1184, 6 April 2013〕〔(Review: Exjade side effects )〕 ==Properties of deferasirox==
The half-life of deferasirox is between 8 and 16 hours allowing once a day dosing. Two molecules of deferasirox are capable of binding to 1 atom of iron which are subsequently eliminated by fecal excretion. Its low molecular weight and high lipophilicity allows the drug to be taken orally unlike deferoxamine which has to be administered by IV route (intravenous infusion). Together with deferiprone, deferasirox seems to be capable of removing iron from cells (cardiac myocytes and hepatocytes) as well as removing iron from the blood.
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「Deferasirox」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|